Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in Platinum-Resistant Ovarian Cancer
NCT04718376Phase 1Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome in ovarian cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Adverse Events (AEs) up to 36 months. Started Jan 2021; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04718376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718376.